$0.00
Shopping Cart
Facebook-f Instagram
DONATE
Donate

Clinical Trial Record

Return to Clinical Trials

NALIRI-XELOX+AK104 for First-line Treatment of Advanced PDAC

2024-04-17

2026-08-30

2026-12-30

30

Study Overview

NALIRI-XELOX+AK104 for First-line Treatment of Advanced PDAC

This study is a single-center, Phase II Study to assess the efficacy and safety of the regimen of Nanoliposomal Irinotecan and XELOX (NALIRI-XELOX) in combination with Cadonilimab in subjects with advanced pancreatic ductal adenocarcinoma who have not previously received systemic treatment.

N/A

  • Nanoliposomal Irinotecan
  • Cadonilimab
  • Oxaliplatin
  • Capecitabine
  • First-Line
  • Advanced Cancer
  • Pancreatic Adenocarcinoma
  • Drug Use
  • DRUG: Nanoliposomal Irinotecan+Oxaliplatin +Capecitabine+Cadonilimab
  • NCC4398

Study Record Dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Registration Dates Results Reporting Dates Study Record Updates

2024-05-05  

N/A  

2024-12-19  

2024-05-05  

N/A  

2024-12-24  

2024-05-08  

N/A  

2024-12  

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

Design Details

Primary Purpose:
Treatment

Allocation:
Na

Interventional Model:
Single Group

Masking:
None

Arms and Interventions

Participant Group/ArmIntervention/Treatment
EXPERIMENTAL: NALIRI-XELOX+AK104

Every 2 weeks as a cycle: 1. Nanoliposomal Irinotecan: 47.1mg/m2, iv, d1; 2. Cadonilimab: 6mg/kg, iv, d3; 3. Oxaliplatin: 70mg/m2, iv, d1; 4. Capecitabine: 1000mg/m2, bid, po, d1-d7; Re-evaluate patients every three cycles. If the patient has been treate

DRUG: Nanoliposomal Irinotecan+Oxaliplatin +Capecitabine+Cadonilimab

  • Use the above medications on a regular basis
Primary Outcome MeasuresMeasure DescriptionTime Frame
Objective Response Rate (ORR)ORR of regimen of NALIRI-XELOX+AK1042 years
Secondary Outcome MeasuresMeasure DescriptionTime Frame
Duration of Response (DoR)2 years
Disease Control Rate (DCR)2 years
Median Progression-Free Survival (mPFS)1 years
12-month PFS rate12 months
Median Overall Survival (mOS)2 years
Incidence of Treatment-Emergent Adverse Events [Safety and Tolerability] Adverse Events (AEs) Incidence, Serious Adverse Events (SAE) Incidence2 years

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Name: lin yang

Phone Number: 13611267380

Email: linyangcicams@126.com

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person’s general health condition or prior treatments.

Ages Eligible for Study:
ALL

Sexes Eligible for Study:
18 Years

Accepts Healthy Volunteers:

    Inclusion Criteria:
    1. Age ≥18, male or female; 2. Has histologically or cytologically confirmed pancreatic ductal adenocarcinoma (PDAC); 3. Has not received prior systemic treatment for their locally advanced or metastatic PDAC; 4. Has presence of measurable disease as defined by Response Evaluation Criteria in Solid Tumours (RECIST 1.1); 5. Has a performance status of 0 or 1 on the Eastern Cooperative Oncology Group (ECOG) Performance Status; 6. Has a life expectancy of at least 3 months; 7. Has adequate organ function; 8. If female of childbearing potential, have a negative serum pregnancy test within 7 days prior to first trial treatment; 9. If female of childbearing potential or a male subject with a partner with childbearing potential, be willing to use a highly effective method of contraception (with a failure rate of less than 1.0% per year) from first study treatment to 24 weeks after completion of the trial treatment.
    Exclusion Criteria:
    1. Untreated active CNS metastasis or leptomeningeal metastasis. 2. Is currently participating and receiving an investigational drug or has participated in a study of an investigational drug within 4 weeks or within 5 times of half-life (no less than 2 weeks), whichever is shorter prior to the first dose of trial treatment; 3. Has received other anti-tumor treatment within 4 weeks or within 5 times of half-life (no less than 2 weeks), whichever is shorter prior to the first trial treatment; 4. Major surgery for any reason, except diagnostic biopsy, within 4 weeks of the first administration of trial treatment and/or if the subject has not fully recovered from the surgery within 4 weeks of the first administration of trial treatment; 5. Curative radiation within 3 months of the first dose of trial treatment. Radiation to more than 30% of the bone marrow or with a wide field of radiation should not be used within 4 weeks prior to the first administration of trial treatment; 6. Subjects receiving immunosuppressive agents (such as steroids) for any reason should be tapered off these drugs before initiation of trial treatment (with the exception of subjects with adrenal insufficiency, who may continue corticosteroids at physiologic replacement doses, equivalent to < 10 mg prednisone daily, inhaled steroids and topical use of steroids); 7. Vaccination within 28 days of the first administration of trial treatment, except for administration of inactivated vaccines (e.g., inactivated influenza vaccines); 8. Has interstitial lung disease, or a history of pneumonitis that required oral or intravenous glucocorticoids to assist with management; 9. History or current active autoimmune disease that might deteriorate when receiving an immunostimulatory agent； 10. Previous malignant disease History of uncontrolled intercurrent illness Prior therapy with any antibody/drug targeting T cell coregulatory proteins Known severe hypersensitivity reactions to antibody drug； 11. Is pregnant or breastfeeding; 12. Other medical conditions that at the discretion of investigator interfere with the requirements of the trial in terms of safety or efficacy evaluation, or treatment compliance.

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Publications

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

General Publications

No publications available

NPCF Pop up

Make-A-Will Month

Snag 6508be92
Learn More
Donate Now Online
Other Ways to Donate